Saphnelo [®] ((anifrolumab-fnia)) Injectable
Medication	Precertification F	Request

Page 1 of 2

♥aetna®

Please indicate:

(All fields must be completed and legible for precertification review.)

Start of treatment: Start date / /
Continuation of therapy: Date of last treatment /

 Aetna
 Precertification
 Notification

 Phone:
 <u>1-866-752-7021</u>
 (TTY: <u>711</u>)

 FAX:
 <u>1-888-267-3277</u>

For Medicare Advantage Part B: Please Use Medicare Request Form

🗌 Continu	uation of therapy: Date o	of last treatment	1	/				
Precertification Requested B	y:			Phone:		Fax:		
A. PATIENT INFORMATION	·							
First Name:			Last I	Name:				
Address:			City:			State:	ZIP:	
Home Phone:	Work	A Phone:	,		Cell Phone:			
DOB:	Allergies:				Email:			
Current Weight: Ib		Height:		inches or				
B. INSURANCE INFORMATION	_				0113			
Aetna Member ID #:		Doos patient have	othor					
Group #:				her coverage?				
Insured:		Insured:						
Medicare: Yes No If y	-		Medi	caid: 🗌 Yes 📋	No If yes, pi	rovide ID #:		
C. PRESCRIBER INFORMATION	Ν				(0)			
First Name:		Last Name:	<u> </u>		(Спеск Оп		D.O. 🗌 N.P. 🗌 P.A.	
Address:				City:			ZIP:	
Phone: F	ax:	St Lic #:	1	NPI #:	DEA #:	UPI	N:	
Provider Email:		Office Contact Nan	ne:			Phone:		
Specialty (Check one): Rhe	umatologist 🔲 Other:							
D. DISPENSING PROVIDER/AD	MINISTRATION INFORMA	TION						
Place of Administration: Self-administered Physician's Office Outpatient Infusion Center Phone: Center Name:			Dispensing Provider/Pharmacy: Patient Selected choice Physician's Office Retail Pharmacy Specialty Pharmacy Other: Name:					
 Agency Name:				Address:				
Administration code(s) (CPT):			Phone: Fax:					
Address:				TIN:		PIN:		
E. PRODUCT INFORMATION				_				
Request is for: Saphnelo (anit				Frequency:				
F. DIAGNOSIS INFORMATION -								
Primary ICD Code:		-						
G. CLINICAL INFORMATION -	•	n must be completed	in its <u>e</u>	<u>entirety</u> for all precer	tification reque	sts.		
For ALL Requests (clinical docu								
 Yes No Is this infusion request in an outpatient hospital setting? Yes No Has the patient experienced an adverse event with the requested product that has not responded to conventional interventions (e.g., acetaminophen, steroids, diphenhydramine, fluids, other pre-medications) or a severe adverse event (anaphylaxis, anaphylactoid reactions, myocardial infarction, thromboembolism, or seizures) during or immediately after an infusion? Yes No Yes No Does the patient have severe venous access issues that require the use of special interventions only available in the outpatient hospital setting? 								
 Yes No Does the patient have significant behavioral issues and/or physical or cognitive impairment that would impact the safety of the infusion therapy AND the patient does not have access to a caregiver? Please provide a description of the behavioral issue or impairment: Yes No Is the patient medically unstable which may include respiratory, cardiovascular, or renal conditions that may limit the patient's ability to tolerate a large volume or load or predispose the patient to a severe adverse event that cannot be managed in an alternate setting without appropriate medical personnel and equipment? 								
	> Please provide a descrip		□ Re □ Re	rdiovascular: spiratory: nal: ner:				



Saphnelo™ (anifrolumab-fnia) Injectable Medication Precertification Request

Page 2 of 2

(All fields must be completed and legible for precertification review.)

 Aetna Precertification Notification

 Phone:
 <u>1-866-752-7021</u> (TTY: <u>711</u>)

 FAX:
 <u>1-888-267-3277</u>

For Medicare Advantage Part B: Phone: <u>1-866-503-0857</u> (TTY: <u>711</u>) FAX: <u>1-844-268-7263</u>

Patient First Name	Patient Last Name	Patient Phone	Patient DOB				
G. CLINICAL INFORMATION (continu	ued) – Required clinical information must b	e completed in its <u>entirety</u> for all pre	certification requests.				
☐ Yes ☐ No Will the patient be using the requested drug in combination with other biologics?							
For Initiation of Therapy (clinical documentation required):							
Active systemic lupus erythematosus (SLE)							
Yes No Does the patient have severe active central nervous system (CNS) lupus [including seizures that are attributed to CNS lupus, psychosis, organic brain syndrome, cerebritis, or CNS vasculitis requiring therapeutic intervention within 60 days before initiation of the requested drug]?							
☐ Yes ☐ No Does the patient have severe active lupus nephritis?							
Yes No Prior to initiating therapy, is the patient positive for autoantibodies relevant to systemic lupus erythematosus (e.g., ANA, anti-ds DNA, anti-Sm, antiphospholipid antibodies, complement proteins)?							
Yes No Is the patient currently receiving a stable standard treatment regimen for systemic lupus erythematosus with any of the following (alone or in combination)?							
Please identify current treatment:							
Glucocorticoids (e.g., prednisone, methylprednisolone, dexamethasone)							
Antimalarials (e.g., hydroxychloroquine)							
Immunosuppressives (e.g., azathioprine, methotrexate, mycophenolate, cyclosporine, cyclophosphamide)							
For Continuation of Therapy (clinical	documentation required):						
Yes No Has the patient achieved or maintained a positive clinical response as evidenced by low disease activity or improvement in signs and symptoms of the condition?							
H. ACKNOWLEDGEMENT							
Request Completed By (Signature Required): Date: / /							
Any person who knowingly files a request for authorization of coverage of a medical procedure or service with the intent to injure, defraud or deceive any insurance company by providing materially false information or conceals material information for the purpose of misleading, commits a fraudulent							

The plan may request additional information or clarification, if needed, to evaluate requests.

insurance act, which is a crime and subjects such person to criminal and civil penalties.